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This article applies methods of latent class analysis(LCA) to data on lifetime illicit drug use in order to
determine whether qualitatively distinct classes of
illicit drug users can be identified. Self-report data on
lifetime illicit drug use (cannabis, stimulants, hallu-
cinogens, sedatives, inhalants, cocaine, opioids and
solvents) collected from a sample of 6265 Australian
twins (average age 30 years) were analyzed using
LCA. Rates of childhood sexual and physical abuse,
lifetime alcohol and tobacco dependence, symptoms
of illicit drug abuse/dependence and psychiatric
comorbidity were compared across classes using
multinomial logistic regression. LCA identified a 
5-class model: Class 1 (68.5%) had low risks of the
use of all drugs except cannabis; Class 2 (17.8%) had
moderate risks of the use of all drugs; Class 3 (6.6%)
had high rates of cocaine, other stimulant and hallu-
cinogen use but lower risks for the use of sedatives
or opioids. Conversely, Class 4 (3.0%) had relatively
low risks of cocaine, other stimulant or hallucinogen
use but high rates of sedative and opioid use. Finally,
Class 5 (4.2%) had uniformly high probabilities for
the use of all drugs. Rates of psychiatric comorbidity
were highest in the polydrug class although the
sedative/opioid class had elevated rates of depres-
sion/suicidal behaviors and exposure to childhood
abuse. Aggregation of population-level data may
obscure important subgroup differences in patterns
of illicit drug use and psychiatric comorbidity. Further
exploration of a ‘self-medicating’ subgroup is needed.
A recurrent finding in the literature is that individuals
who use one type of drug are also considerably more
likely to use other drugs (Darke et al., 2003;
Degenhardt et al., 2001; Hasin et al., 1988; Kendler
et al., 2003; Leri et al., 2003; Tsuang et al., 1998;
Zinkernagel et al., 2001). While polydrug use is
common, it is not the case that all individuals who
have used one drug class have also used all — or any
— other classes of drug. Differences in polydrug use
may simply reflect differences in availability and
opportunity to use (Lillie-Blanton et al., 1993; Morral
et al., 2002). It may also be possible, however, to
subtype drug users on the basis of different patterns
of polydrug use. There have been only limited prior
attempts to classify individuals on the basis of differ-
ent patterns of drug use, despite numerous previous
attempts to subtype alcohol and other drug use on the
basis of various factors including age of onset (Clark
et al., 1998), personality (Cloninger, 1987) and psy-
chiatric comorbidity (Schuckit et al., 1969), and to
develop multidimensional typologies (Babor et al.,
1992). These efforts have largely been confined to
consideration of aspects of abuse/dependence on
single drug categories. There has been relatively little
consideration of the extent to which different patterns
of use across multiple drug classes may identify sub-
groups of individuals with distinct patterns of drug
use and comorbidity.
One approach to studying this issue involves the
use of latent class analysis (LCA; McCutcheon, 1987).
A major advantage of LCA is that it assigns individuals
to classes on a probabilistic basis, allowing comparison
of rates of comorbid psychopathology and other corre-
lates across classes. We have been unable to identify
any previous published work applying these techniques
to measures of illicit drug use in the general popula-
tion. Thus, in this article we report on the results of a
series of LCAs to assess the extent to which patterns of
lifetime use of eight different drug categories (cannabis,
cocaine, stimulants, sedatives, opioids, solvents,
inhalants) identify different subtypes of illicit drug user.
We further explore the extent to which such groups
may differ in respect to psychiatric comorbidity.
While illicit drug use has been shown to be associ-
ated with increased risks for a range of psychiatric
comorbidities, including antisocial behavior, mood dis-
orders and suicidal behaviors (e.g., Degenhardt et al.,
2003; Kidorf et al., 2004; Kranzler & Rounsaville,
1998; Rey & Tennant, 2002), it is not the case that all
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individuals who use drugs meet criteria for these dis-
orders. It is therefore possible that different subgroups
of illicit drug users may be distinguished by qualita-
tively distinct patterns of psychiatric comorbidity,
although such a possibility has been largely neglected
by the common practice of contrasting rates of psychi-
atric morbidity between users and nonusers of specific
drug classes. Thus, a second aim of this study is to
explore the extent to which subgroups of lifetime illicit
drug users, identified on the basis of LCA, exhibit dis-
tinct patterns of psychiatric comorbidity. Such analyses
have the added advantage of providing an external vali-
dation of the extent to which LCA may have identified
qualitatively distinct subgroups of illicit drug user.
Methods
Sample
Interviewees were members of the young adult cohort of
the Australian Twin Registry, a volunteer twin panel
who were born between 1964 and 1971. Nearly all were
first registered with the panel between 1980 and 1982
by their parents in response to approaches either
through Australian school systems or via mass media
appeals. Twins were first contacted as adults in 1989 by
means of a mailed questionnaire. The data presented in
this report are derived from responses to a telephone
interview conducted by lay interviewers during the
period 1996 to 2000. Informed consent was obtained
from participants prior to administering the interviews,
as approved by the institutional review boards of
Washington University-St Louis and the Queensland
Institute of Medical Research.
The initial panel recruited between 1980 and 1982
comprised 4262 twin pairs. Of these, 5.9% of pairs
could not be located even after extensive efforts to locate
family members. Diagnostic interviews were conducted
during 1996 to 2000 with 6265 individuals, which com-
prised 78.1% of the remaining 8020 twins. Allowing for
individuals who could not be located; who were
deceased, incapacitated or otherwise unable to complete
a telephone interview; or who were not assigned for
interview by the end of the study, the individual response
rate increases to 84.2%. The median age at assessment
of respondents was 30 (range = 24–36).
Assessments
A structured diagnostic interview designed for genetic
studies on alcoholism, the SSAGA (Bucholz et al.,
1994), was adapted for telephone use and updated for
Diagnostic and Statistical Manual of Mental Disorders
(4th ed.; DSM-IV; American Psychiatric Association,
1994) diagnostic criteria.
Psychiatric disorders. The modified SSAGA collected
information on full DSM-IV criteria for major depres-
sive disorder as well as separate information on
whether subjects had ever contemplated or attempted
suicide. DSM-IV conduct disorder, alcohol dependence
and nicotine dependence were assessed using the mod-
ified SSAGA and diagnoses were assigned by
computer algorithm. The prevalence of these disorders
in the entire sample were (a) major depressive disor-
der, 22.9% of males and 33.0% of females; (b)
suicidal ideation, 26.3% of males and 26.4% of
females; (c) suicide attempt, 3.4% of males and 4.8%
of females; (d) conduct disorder, 20.0% of males and
7.8% of females; (e) nicotine dependence, 32.8% of
males and 29.0% of females; (f) alcohol dependence,
30.6% of males and 15.6% of females.
Symptoms of illicit drug abuse/dependence. Individuals
reporting any use of cannabis, sedatives, cocaine/other
stimulants or opioids on at least a monthly basis were
asked additional questions concerning the extent to
which they may have experienced symptoms of drug
abuse (use in physically hazardous situations, use inter-
fering with major role obligations) or dependence (using
more frequently or for longer periods than intended,
needing larger amounts to achieve an effect [tolerance],
continued use despite use causing emotional problems,
recurrent desire to cut down on use). For the current
analysis, a measure of abuse/dependence symptomatol-
ogy was constructed by classifying an individual who
reported any of these symptoms as showing symptoms
of abuse/dependence for that drug class.
Childhood sexual abuse. Respondents were also
asked a series of questions concerning their exposure
to unwanted sexual contact, sexual molestation or
rape. A composite measure was constructed that clas-
sified respondents who reported any such experiences
before the age of 18 years as having a history of child-
hood sexual abuse (Nelson et al., 2002). Reported
exposure to childhood sexual abuse was 5.7% for
males and 17.0% for females.
Childhood physical abuse. Respondents were asked a
series of questions concerning whether they had been
physically abused as a child. An individual was classi-
fied as being exposed to childhood physical abuse if
he/she reported (a) sometimes or often being physically
punished so hard that they hurt the next day, (b) being
physically injured on purpose by an adult relative, or
(c) being physically abused as a child. Reported expo-
sure to childhood physical abuse was 2.9% for males
and 4.2% for females.
Statistical Analyses
LCA assumes that symptom (in this case drug use) fre-
quency can be explained by the existence of a small
number of mutually exclusive classes, with each class
having a distinct profile of item endorsement probabili-
ties (i.e., patterns of drug use). A critical implication of
this assumption is that the observed variables are statis-
tically independent conditional on class membership.
A series of models (2–8 class) were fitted to the data
from both members of the twin pair by LCA using
Mplus (v3.1; Muthén & Muthén, 2004). Standard
errors were adjusted to account for familial clustering
of data by employing a maximum likelihood ratio
(MLR) sandwich estimator, which is robust to noninde-
pendence of observations. MLR uses random starting
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values to optimize the parameters. In the initial stage,
500 random sets of starting values were used and a
maximum of 100 iterations were allowed for each
initial stage. In the final stage, 10 optimizations were
allowed. The conservative Bayesian Information
Criterion (BIC) was used to select the most parsimo-
nious model that also provided a good fit to the data.
These models were fitted to the data from all individu-
als studied, including those who reported no lifetime
illicit drug use.
To investigate the discriminant validity of our pre-
ferred LCA solution, we tested for associations between
class membership and (a) lifetime rates of substance
dependence including DSM-IV-based nicotine and
alcohol dependence, (b) measures of psychiatric illness
including lifetime history of DSM-IV major depressive
and conduct disorders, suicidal ideation, suicide
attempt and a nondiagnostic measure of social anxiety,
(c) exposure to sexual and physical abuse during child-
hood, (d) symptoms of abuse or dependence on
cannabis, cocaine/other stimulants, sedatives or opioids.
Each individual was assigned the most probable class
membership associated with their self-report drug use
profile under the preferred latent class model. Dummy
predictor variables were created for membership in
Classes 2 … n, using the first (no/minimal use) class as
the reference group, and multinomial logistic regression
models were fitted in STATA (StataCorp, 1999), using
the Huber-White robust variance estimator to correct
for nonindependence of observations on twin pairs.
To further explore the influence of trauma on latent
class membership, we selected four covariates: gender
(0 = female, 1 = male), conduct disorder, childhood
sexual abuse and physical abuse for inclusion in the
latent class modeling. The multinomial logistic
regression of the latent class on each individual
covariate was estimated in a full model (the best-fitting
solution from LCA). Next, we fit a reduced model where
regression coefficients were independently estimated for
each of the four covariates but were constrained across
latent classes. A series of intermediate models, where
constraints were imposed across latent classes with
similar regression coefficients, were also fit and the
change in the –2 loglikelihood fit of the models was
compared. Model fitting was done in Mplus using a
standard numerical integration algorithm.
Results
Associations Between the Use of Different Illicit Drugs
Table 1 shows the odds ratios and their associated
95% confidence intervals (CI) between measures of
lifetime use of eight classes of illicit drugs including
cannabis, stimulants, hallucinogens, sedatives,
inhalants, cocaine, opioids and solvents. The table
also shows the prevalence of drug use among males
and females. The results in this table show consistently
high associations between the lifetime use of different
drug categories with odds ratios (OR) ranging from
4.2 to 51.2. There were particularly strong associa-
tions between cocaine use and both cannabis
(OR = 51.2, 95% CI = 22.8–114.8) and stimulant
use (OR = 39.3, 95% CI = 28.9–53.3) and between
hallucinogen use and the use of cocaine (OR = 34.0, 
95% CI = 26.6–43.4), stimulants (OR = 25.5, 
95% CI = 21.3–30.7) and cannabis (OR = 49.9, 
95% CI = 29.3–84.8).
Latent Class Analysis of Lifetime Use of Different Drug Classes
A 5-class model was identified as giving the best fit to
the data, by BIC. Specifically, the 5-class solution had
the lowest BIC (28,395.2 compared with 28,397.0 for
525
Table 1
Odds Ratios (95% Confidence Intervals) Between Measures of Lifetime Drug Use
Cannabis Stimulants Hallucinogens Sedatives Inhalants Cocaine Opioids Solvents
Cannabis
Stimulants 12.2
(9.8–15.2)
Hallucinogens 49.9 25.5
(29.3–84.8) (21.3–30.7)
Sedatives 4.6 7.6 7.8
(3.6–5.9) (6.4–9.2) (6.4–9.4)
Inhalants 11.5 12.7 15.6 7.5
(8.1–16.2) (10.4–15.4) (12.9–19.0) (6.1–9.2)
Cocaine 51.2 39.3 34.0 8.5 18.8
(22.8–114.8) (28.9–53.3) (26.6–43.4) (6.8–10.6) (15.1–23.5)
Opioids 4.2 8.8 9.5 14.7 8.2 11.1
(3.2–5.5) (7.1–10.9) (7.7–11.7) (11.8–18.3) (6.6–10.2) (8.8–14.1)
Solvents 14.1 6.3 7.4 8.4 8.1 5.0 5.8
(6.6–30.3) (4.6–8.9) (5.3–10.3) (6.0–11.8) (5.8–11.4) (3.4–7.4) (4.0–8.5)
Prevalence
Males 68.8 25.9 18.6 9.2 13.1 8.8 8.1 3.5
Females 53.2 16.8 9.1 9.0 5.6 4.9 5.5 1.5
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the 4-class solution and 28442.9 for the 6-class solu-
tion). The symptom endorsement probabilities (SEPs)
for each of the eight drug use measures derived from
the 5-class model are displayed in Figure 1.
Consideration of the SEPs for each item, along with
class prevalence, provides a substantive interpretation
of each of the five classes:
1. Individuals in the first class (68.5%) had near zero
probabilities of the use of all drug classes except
cannabis. The probability of cannabis use (42.8%)
in this class was substantial, reflecting the high
prevalence of cannabis use in this sample.
2. The second class (17.8%) had high probabilities of
cannabis use (99.8%), stimulant use (43.6%) and
hallucinogen use (22.3%) but relatively low proba-
bilities of the use of other drug classes, with these
probabilities ranging from 3.7% for cocaine to
12% for sedatives. Thus, they could be character-
ized as individuals with moderate rates of lifetime
illicit drug use, with most of their drug use being
confined to cannabis, stimulants and hallucino-
gens, the three most commonly used drug classes
in this sample.
3. The third group consisted of 6.6% of the sample
and, in addition to near universal rates of cannabis
use, were characterized by increased risks of stimu-
lant use (89.9%), cocaine use (47.8%),
hallucinogen use (76.4%) and, to a lesser extent,
inhalant use (38.4%). In contrast, probabilities of
solvent (0.5%), sedative (10.6%) and opioid use
(10.8%) by this group were low. Thus, members of
this group can best be characterized as having high
rates of cannabis, cocaine, other stimulant and hal-
lucinogen use but low rates of use of sedatives and
opioids.
4. In contrast, members of the fourth group, which
comprised 3.0% of the sample, had elevated prob-
abilities of sedative use (52.5%) and opioid use
(53.2%) but relatively low risks of the use of other
drugs. In fact, their probability of hallucinogen use
(4.6%) and cocaine use (4.4%) approximated
those for Latent Class 1 and they had the second
lowest prevalence of cannabis use (70.5%). It
would appear that members of this group are best
characterized as having elevated risks for the non-
medicinal use of prescription drugs but relatively
low rates of other drug use.
5. The fifth class (4.2%) showed the highest proba-
bilities of the use of each drug class, with these
probabilities ranging from 22.7% for solvents to
99.9% for cannabis. These individuals are best
characterized as extreme polydrug users with high
risks for the use of all drug classes.
Perhaps the most striking feature of this graph is the
extent to which the lines cross, indicating that the analy-
sis has identified classes within the  sample who have
qualitatively distinct patterns of drug use rather than
simply reflecting differences in the extent of drug use.
Rates of Lifetime Symptoms of Illicit Drug Abuse/Dependence 
and Latent Class Membership
Figure 2 shows the percentage of individuals in each
latent class experiencing at least one symptom of
abuse or dependence on cannabis, cocaine/other stim-
ulants, sedatives or opioids. There were dramatic
differences between latent classes in rates of illicit drug
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Figure 1
Symptom endorsement profiles by class membership.
abuse/dependence symptoms. Of particular note, there
was evidence that members of Latent Class 4, who
were characterized by high rates of lifetime sedative and
opioid use, had elevated rates of symptoms of both
sedative and opioid abuse/dependence. This indicates
that individuals in this class were characterized not
solely by lifetime use of these substances but were also
at increased risks for symptoms of abuse/dependence.
Conversely, members of Latent Class 3, who had been
characterized by high rates of cocaine/other stimulant
and hallucinogen use, did not have elevated symptoms
of sedative or opioid abuse/dependence. They did,
however, have elevated rates of symptoms of cannabis
and cocaine/other stimulant abuse or dependence.
LCA was successful in identifying a group with
high probabilities of experiencing drug-related prob-
lems. Although members of Latent Class 5 comprised
only 4.2% of the sample, they accounted for 47.9% of
all those experiencing opioid-related problems and
45.9% of all those experiencing cocaine/other stimu-
lant problems.
Rates of Exposure to Traumatic Events and Psychiatric Disorders
Across Latent Classes
The results of a series of multinomial logistic regres-
sion models are summarized in Table 2, which shows
the OR describing the risks of each of the substance
abuse/dependence and mental health outcomes relative
to members of the first group. There were significant
differences in the gender composition of the five latent
classes with Classes 2 (moderate use), 3 (party drugs)
and 5 (polydrug) having a significantly higher propor-
tion of males, relative to the first latent class. In
addition the proportion of males in the polydrug class
(65.4%) was significantly higher than the correspond-
ing proportions in Classes 2 (52.2%) or 3 (58.6%). In
contrast, the majority of Class 4 (sedatives/ opioids)
were female (65.5%). Relative to members of the first
latent class, exposure to traumatic events (childhood
sexual abuse, physical abuse) was elevated in all four
drug use classes, and was particularly high in members
of the sedative/opioid and extreme polydrug use classes.
Table 2 also shows that rates of substance depen-
dence and psychiatric disorders were significantly
elevated for members of Latent Classes 2, 3, 4 and 5
relative to the first latent class. However, there were
also important differences between groups 2 to 5 in
risks of these outcomes. Specifically, while members of
Latent Class 2 (moderate drug use) generally had the
lowest profile of risk, members of Class 4 (sedative,
opioid use) had risks of several outcomes that were
equivalent to (nicotine dependence, alcohol depen-
dence, conduct disorder, social anxiety) or
significantly lower than (cannabis dependence) risks of
these outcomes in Group 2. In contrast, members of
Latent Class 4 had dramatically elevated risks of
major depressive disorder, suicidal ideation and
suicide attempt.
Members of Latent Class 3, who were character-
ized by high probabilities of cocaine and other
stimulant and hallucinogen use, had rates of these out-
comes that were elevated relative to members of the
first latent class but were generally similar to risks in
the moderate use group (Latent Class 2). However,
while they had greatly elevated odds of meeting crite-
ria for cannabis dependence (OR = 25.22, 95% CI =
18.76–33.90), their odds of social anxiety did not
differ significantly from those among members of
Group 1 (OR = .86, 95% CI = 0.66–1.22) and were,
in fact, significantly lower than the corresponding
risks among members of Latent Classes 2, 4 and 5.
Finally, members of the ‘polydrug use’ group had
dramatically elevated rates of each of the substance
dependence and mental health outcomes: relative to
members of the no use/cannabis only group odds of
these outcomes were 1.6 to 12.1 times higher in
members of the polydrug use group.
The regression of each latent class (with the first
latent class serving as the reference group) on physical
abuse, childhood sexual abuse, gender and conduct dis-
order was significant across a majority of the latent
classes (–2LL = 13,413.01 with 60 estimated parame-
ters). The reduced model where the influence of each
covariate was equated across latent classes did not fit
the data well (–2LL = 13,515.45 for 48 parameters,
∆χ2 = 102.44 for ∆df = 12). The best fitting model
(–2LL = 13,428.67 for 52 parameters, ∆χ2 = 15.75 for
∆df = 8) allowed us to (a) constrain the regression coef-
ficients for gender across Latent Classes 2, 3 and 5
(β = 1.054, SE = 0.1) but not Class 4 (β = –0.38,
SE = 0.3), (b) constrain the regression coefficients for
conduct disorder across Latent Classes 2, 3 and 4
(β = 1.94, SE = 0.2) but not Class 5 (β = 3.36, SE = 0.2),
(c) constrain the regression coefficient for childhood
sexual abuse across Classes 4 and 5 (β = 1.70, SE = 0.2)
and across Classes 2 and 3 (β = 0.96, SE = 0.2), (d) con-
strain the nonsignificant regression coefficient for
physical abuse across Classes 3 and 5 (β = 0.20,
527
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Rates (%) reporting at least one symptom of abuse or dependence 
on cannabis, cocaine/other stimulants, sedatives and opioids by 
class membership.
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SE = 0.4) and across Classes 2 and 4 (β = 3.35,
SE = 0.2) where these coefficients were significant.
Discussion
In this article we have examined patterns of polydrug
use in a large sample of young adult twins recruited
from the general population. We confirmed previous
findings (Darke et al., 2003; Degenhardt et al., 2001;
Hasin et al., 1988; Kendler et al., 2003; Leri et al.,
2003; Tsuang et al., 1998; Zinkernagel et al., 2001)
that the use of one drug is associated with dramati-
cally elevated risks for the use of other drugs, with
these odds ratios ranging from 4.2 to 51.2. LCA
identified a 5-class solution in which three classes
were distinguished by quantitative differences in the
probabilities of all drug use: Class 1 had low risks of
the use of all drugs (with the exception of cannabis),
Class 2 had moderate risks of the use of all drugs
and Class 5 was distinguished by uniformly high
probabilities for the use of all drugs. The analysis
also identified two further latent classes that showed
qualitatively distinct patterns of drug use: Class 3
had high rates of cocaine use, other stimulant use
and inhalant use but lower risks for the use of seda-
tives or opioids. In contrast, Class 4 had relatively
low risks of cocaine, other stimulant or inhalant use
but high rates of sedative and opioid use.
Further analysis revealed marked differences between
the five latent classes in risks of substance abuse/
dependence symptomatology and mental health prob-
lems. In particular, while all substance use groups had
generally elevated rates of these outcomes relative to
the nonuse/cannabis only class, distinct patterns of
comorbidity emerged. Most strikingly, members of
Latent Class 4, who had been characterized by high
rates of opioid and sedative use, had dramatically ele-
vated rates of major depressive disorder, suicidal
ideation and suicide attempt but only moderately ele-
vated risks of other disorders. This pattern of results is
consistent with the interpretation that members of this
group may have been experimenting with — and later
experiencing abuse/dependence symptomatology as a
result of — the nonmedicinal use of prescription drugs
in an attempt to self-medicate aversive mental states.
Further analyses indicated a moderate degree of
within-twin pair concordance for membership of
Latent Class 4 among monozygotic female twin pairs
only, suggesting some heritable influences on risks of
membership of this group among females.
The differential pattern of comorbidity observed
across classes highlights potential heterogeneity in
mechanisms underlying comorbidity and may also
help to partially explain apparently contradictory
and controversial findings in the research literature
regarding such mechanisms as the self-medication
hypothesis (Khantzian, 1985, 1997; Markou et al.,
1998). Specifically, they suggest that such mechanisms
may indeed play an important role in the etiology of
comorbidity for some individuals but that such individu-
als may form a relatively small proportion of the general
population and findings and processes unique to such
groups may be obscured in analyses which fail to consider
potential within-population sources of heterogeneity.
Importantly, the two groups characterized by high
rates of sedative and opioid use (and symptoms of
abuse and dependence on these drug classes; Latent
Classes 4 and 5) also had high levels of exposure to
childhood physical and sexual abuse. This is consistent
with a growing body of literature demonstrating that
childhood abuse plays a causal role in the development
of substance use problems and other psychopathology
(Fergusson et al., 1996; Nelson et al., 2002). None-
theless, given our reliance on retrospective reports we
cannot be certain whether depressive symptomatology
preceded the onset of drug use, a necessary condition
for our contention that drug use in this subgroup of the
sample represents attempts at self-medication. While
both the drug use characteristics of this sample (pre-
dominantly misuse of pharmaceuticals with relatively
low rates of use of recreational drugs such as
cocaine) and related factors (e.g., high rates of expo-
sure to childhood abuse) support the contention that
drug use for this group represents attempts at self-
medication, it remains possible that drug use could,
in fact, have preceded the onset of depressive symp-
tomatology for this group. Thus further replication,
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Table 2
Odds Ratios (95% Confidence Intervals) Between Lifetime Substance
Abuse/Dependence, Major Depression and Suicidal Behaviors and Latent
Class Membership
Class 2 Class 3 Class 4 Class 5
Gender (male) 1.6a 2.0a,b .8c 2.7b
(1.3–1.8) (1.6–2.6) (.5–1.1) (2.0–3.6)
Physical abuse 2.2a 2.4a 3.8b 4.9b
(1.8–2.8) (1.7–3.5) (2.8–5.3) (3.2–7.7)
Sexual abuse 2.0a 2.2a 4.0b 4.1b
(1.7–2.5) (1.6–3.0) (2.6–6.2) (3.1–5.5)
Substance dependence
Nicotine 3.3a 3.8a 2.8a 6.9b
(2.8–3.8) (3.0–4.9) (1.9–4.1) (5.3–9.0)
Alcohol 3.4a 4.2a 2.7a 7.6b
(2.9–3.9) (3.3–5.3) (1.8–4.1) (5.8–9.9)
Mental health
Conduct disorder 3.7a 3.7a 2.7a 12.1b
(3.1–4.4) (2.7–4.9) (1.6–4.4) (9.3–15.9)
Social anxiety 1.2a 0.9b 1.6a 1.6a
(1.1–1.4) (0.7–1.1) (1.1–2.4) (1.2–2.1)
Major depressive disorder 1.7a 1.8a 3.5b 3.4b
(1.5–2.0) (1.4–2.3) (2.4–5.1) (2.6–4.4)
Suicidal ideation 2.4a 2.3a 5.1b 6.1b
(2.1–2.8) (1.8–3.0) (3.5–7.5) (4.7–7.9)
Suicide attempt 3.7a 2.1a 7.1b 9.3b
(2.7–5.0) (1.2–3.8) (4.1–12.5) (6.4–13.5)
Note: Odds ratios with the same superscript are not significantly different from each other.
ideally within the context of a prospective design
which addresses issues of temporal ordering, is needed
to test whether the drug use in this subsample does gen-
uinely reflect attempts at self-medication.
Further research is needed both to determine
whether the latent drug use classes identified in this
sample can be replicated in other samples and also to
determine the associations between such latent classes
and a broader array of potential covariates, including
both measures of psychopathology and exposure to
social/family disadvantage and dysfunction. A further
potential limitation concerns our use of a twin sample
and our analyses, that did not fully exploit the genetic
informativeness of the sample, rest on the assumption
that drug use and related processes are the same for
twins as for singletons. Nonetheless, while we would
like to see the current analyses replicated in a sample
of unrelated individuals, the existing literature sup-
ports the assumption that analyses of twin and
singleton samples are likely to lead to the same results
(Kendler et al., 2002).
Finally, these results have implications for gene-
hunting efforts that attempt to identify genes
associated with or linked to increased risks for poly-
substance abuse or dependence (Stallings et al., 2003;
Uhl et al., 2001). Specifically, they suggest that, to the
extent that the phenotype of polysubstance use/abuse
may encompass several distinct subgroups differing in
patterns of drug use, etiology and associated mental
health problems, such efforts are likely to be compro-
mised. Thus, further refinement of polysubstance use
phenotypes may aid in the successful identification of
genetic — and environmental — influences associated
with these patterns of multiple drug use.
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